Furthermore, we intended to assess whether PNR could predict the prognosis of anti‐PD‐1‐containing therapy in patients with advanced solid tumor, such as gastric carcinoma, colon cancer, biliary tract carcinoma, or melanoma. This evidence concerns the gene PDCD1 and gastric carcinoma.